Welcome to our dedicated page for KESTRA MED TECHNOLOGIES news (Ticker: KMTS), a resource for investors and traders seeking the latest updates and insights on KESTRA MED TECHNOLOGIES stock.
Kestra Medical Technologies reports developments as a commercial-stage wearable medical device and digital healthcare company focused on cardiovascular disease. Its updates center on the Cardiac Recovery System platform and the ASSURE WCD, a wearable cardioverter defibrillator used for patients at elevated risk of sudden cardiac arrest.
Recurring news includes fiscal results and revenue guidance, clinical data from the ASSURE WCD post-approval study, product and algorithm updates, healthcare conference presentations, and collaborations aimed at expanding diagnostic insight during cardiac recovery.
Kestra Medical Technologies (Nasdaq: KMTS) reported strong Q1 FY26 financial results, with revenue reaching $19.4 million, a 52% increase year-over-year. The wearable medical device company saw significant growth with 4,205 prescriptions written for its ASSURE® system, up 51% from the previous year. Gross margin expanded to 45.7% from 32.9% year-over-year.
The company raised its FY26 revenue guidance to $88 million, representing 47% growth compared to FY25, up from previous guidance of $85 million. Despite strong top-line growth, Kestra reported a GAAP net loss of $25.8 million and held cash and equivalents of $201.2 million as of July 31, 2025.
Kestra Medical Technologies (Nasdaq: KMTS), a wearable medical device and digital healthcare company, has scheduled its first quarter fiscal 2026 earnings release for Thursday, September 11. The company will host a conference call at 4:30 p.m. Eastern Time to discuss the results.
Interested participants can access the live and archived webcast through the "Events" section of Kestra's investor relations website and are advised to register at least 10 minutes before the call begins.
Biobeat Technologies has appointed Raymond W. Cohen as Chairman of the Board of Directors. The company, which develops wearable medical devices, has received FDA clearance for its innovative patch device that monitors multiple physiological parameters including continuous cuff-less ambulatory blood pressure.
Cohen brings over 40 years of life science industry experience, notably as co-founder and CEO of Axonics, which was acquired by Boston Scientific for $3.7 billion in 2024. Under his leadership, Axonics generated over $1 billion in revenue within four years of commercial launch. Most recently, as chairman of SoniVie, he led its sale to Boston Scientific for $600 million in March 2025.
Kestra Medical Technologies (Nasdaq: KMTS), a wearable medical device and digital healthcare company, has been awarded the 2025 Top Workplaces Industry Award by Energage. The recognition is based on employee feedback through an engagement survey, highlighting Kestra's commitment to maintaining a people-first workplace culture.
CEO Brian Webster emphasized that this achievement reflects the team's dedication to their mission of advancing cardiac care through employee empowerment. The award positions Kestra as an employer of choice in the healthcare sector, with the company's workplace culture being specifically recognized for its focus on employee voice and engagement.
Kestra Medical Technologies (NASDAQ:KMTS), a wearable medical device company, reported strong Q4 and FY2025 results. Q4 revenue reached $17.2 million, up 71% year-over-year, while FY25 revenue hit $59.8 million, a 115% increase from FY24. The company's ASSURE® cardiac recovery system saw 13,193 prescriptions in FY25, up 72% from the previous year.
Gross margins significantly improved to 44.3% in Q4 FY25 from 13.9% in the prior year, and 40.5% for FY25 compared to 1.3% in FY24. Despite growth, the company reported a GAAP net loss of $51.1 million in Q4 and $113.8 million for FY25. Looking ahead, Kestra projects FY26 revenue of $85 million, representing 42% growth.
[ "Revenue grew 115% year-over-year to $59.8 million in FY25", "Significant gross margin expansion to 40.5% in FY25 from 1.3% in FY24", "Strong prescription growth with 13,193 ASSURE® system prescriptions in FY25, up 72%", "Robust cash position of $237.6 million as of April 30, 2025", "Projected 42% revenue growth for FY26 with $85 million guidance" ]Kestra Medical Technologies (Nasdaq: KMTS), a wearable medical device and digital healthcare company, has scheduled its fourth quarter and fiscal year 2025 financial results announcement for Tuesday, July 15, 2025. The company will host a conference call at 4:30 p.m. Eastern Time to discuss the results. Investors can access both the live and archived webcast through the "Events" section of Kestra's investor relations website, with registration recommended at least 10 minutes before the call.
Kestra Medical Technologies (Nasdaq: KMTS), a company specializing in wearable medical devices and digital healthcare, has announced its participation in two major upcoming investor conferences.
The company will present at the following events:
- BofA Securities 2025 Health Care Conference on May 14 at 6:40 p.m. ET
- Goldman Sachs 46th Annual Global Healthcare Conference 2025 on June 11 at 8:00 a.m. ET
Investors and interested parties can access live webcasts and replays of both presentations through Kestra Medical Technologies' investor relations website.